Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Atezolizumab |
Indication/Tumor Type | ovary epithelial cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | ovary epithelial cancer | predicted - sensitive | Atezolizumab | Case Reports/Case Series | Actionable | In a Phase I trial, Tecentriq (atezolizumab) treatment resulted in an objective response rate (ORR) of 22.2% (2/9, 1 complete response, 1 partial response) and a median progression-free survival of 2.9 months in patients with advanced or recurrent ovarian epithelial cancer, ORR was 25% (2/8) in patients with tumor CD274 (PD-L1) expression of 5% or higher and 0% (0/1) in patients with tumor CD274 (PD-L1) expression below 5% (PMID: 31204078; NCT01375842). | 31204078 |
PubMed Id | Reference Title | Details |
---|---|---|
(31204078) | Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. | Full reference... |